Tenaya Therapeutics - Public Comps and Valuation Multiples

Tenaya Therapeutics Overview

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.

Founded

2016

HQ

Employees

Website

tenayatherapeutics.com

Sectors

Drug Development & Therapeutics
Genomics & Personalized Medicine
BioTech
DeepTech

Financials

Last FY Revenue n/a

LTM EBITDA -$93.1M

EV

$136M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Tenaya Therapeutics Financials

As of August 2025, Tenaya Therapeutics reported last 12-month EBITDA of -$93.1M.

In the same period, Tenaya Therapeutics achieved -$100M in LTM net income.

See Tenaya Therapeutics valuation multiples based on analyst estimates

Tenaya Therapeutics P&L

In the most recent fiscal year, Tenaya Therapeutics reported EBITDA of -$107M.

Tenaya Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Tenaya Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$93.1M	XXX	-$107M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$103M	XXX	-$116M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$100M	XXX	-$111M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Tenaya Therapeutics including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$93.1M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$93.1M	Analyst estimates available to subscribers	-$107M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$103M	Analyst estimates available to subscribers	-$116M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$100M	Analyst estimates available to subscribers	-$111M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Tenaya Therapeutics

This financial data table provides comprehensive performance metrics for Tenaya Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$93.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$100M.

Fiscal Year Performance

Fiscal year EBITDA was -$107M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Tenaya Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics has current market cap of $196M, and EV of $136M.

Market Cap Evolution

Tenaya Therapeutics Stock Data

As of September 12, 2025, Tenaya Therapeutics's stock price is $1.

See Tenaya Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$136M	$196M	XXX	XXX	XXX	XXX	$-0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Tenaya Therapeutics Valuation Multiples

Tenaya Therapeutics's trades at n/a EV/Revenue multiple, and -1.3x EV/EBITDA.

See valuation multiples for Tenaya Therapeutics and 15K+ public comps

Tenaya Therapeutics Financial Valuation Multiples

As of September 12, 2025, Tenaya Therapeutics has market cap of $196M and EV of $136M.

Equity research analysts estimate Tenaya Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tenaya Therapeutics has a P/E ratio of -2.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$196M	XXX	$196M	XXX	XXX	XXX
EV (current)	$136M	XXX	$136M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-1.5x	XXX	-1.3x	XXX	XXX	XXX
EV/EBIT	-1.3x	XXX	-1.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-2.0x	XXX	-1.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Tenaya Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Tenaya Therapeutics Margins & Growth Rates

Tenaya Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.

Tenaya Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tenaya Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Tenaya Therapeutics and other 15K+ public comps

Tenaya Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	1%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial